# Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

> **NCT05363449** · PHASE1 · COMPLETED · sponsor: **Therapeutics, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Tinea Cruris
- Tinea Pedis

## Interventions

- **DRUG:** UHE-103 Cream
- **DRUG:** Naftin (naftifine hydrochloride) Cream

## Key facts

- **NCT ID:** NCT05363449
- **Lead sponsor:** Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-17
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363449, "Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05363449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*